203 related articles for article (PubMed ID: 32027482)
21. Rational design of small molecules able to inhibit α-synuclein amyloid aggregation for the treatment of Parkinson's disease.
Vittorio S; Adornato I; Gitto R; Peña-Díaz S; Ventura S; De Luca L
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1727-1735. PubMed ID: 32924648
[TBL] [Abstract][Full Text] [Related]
22. Curcumin modulates α-synuclein aggregation and toxicity.
Singh PK; Kotia V; Ghosh D; Mohite GM; Kumar A; Maji SK
ACS Chem Neurosci; 2013 Mar; 4(3):393-407. PubMed ID: 23509976
[TBL] [Abstract][Full Text] [Related]
23. Discovery of novel 6-hydroxybenzothiazole urea derivatives as dual Dyrk1A/α-synuclein aggregation inhibitors with neuroprotective effects.
AlNajjar YT; Gabr M; ElHady AK; Salah M; Wilms G; Abadi AH; Becker W; Abdel-Halim M; Engel M
Eur J Med Chem; 2022 Jan; 227():113911. PubMed ID: 34710745
[TBL] [Abstract][Full Text] [Related]
24. Ginkgolic acid promotes autophagy-dependent clearance of intracellular alpha-synuclein aggregates.
Vijayakumaran S; Nakamura Y; Henley JM; Pountney DL
Mol Cell Neurosci; 2019 Dec; 101():103416. PubMed ID: 31654699
[TBL] [Abstract][Full Text] [Related]
25. Chitosan nanocarrier for FTY720 enhanced delivery retards Parkinson's disease via PP2A-EzH2 signaling in vitro and ex vivo.
Sardoiwala MN; Karmakar S; Choudhury SR
Carbohydr Polym; 2021 Feb; 254():117435. PubMed ID: 33357908
[TBL] [Abstract][Full Text] [Related]
26. α-Synuclein protects against manganese neurotoxic insult during the early stages of exposure in a dopaminergic cell model of Parkinson's disease.
Harischandra DS; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
Toxicol Sci; 2015 Feb; 143(2):454-68. PubMed ID: 25416158
[TBL] [Abstract][Full Text] [Related]
27. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
[TBL] [Abstract][Full Text] [Related]
28. [Protective effect of curcumin on dopamine neurons in Parkinson's disease and its mechanism].
Wu Y; Liang S; Xu B; Zhang R; Xu L
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2018 May; 47(5):480-486. PubMed ID: 30693689
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis, immunocytochemistry evaluation, and molecular docking investigation of several 4-aminopyridine derivatives as potential neuroprotective agents for treating Parkinson's disease.
Li S; Wei D; Mao Z; Chen L; Yan X; Li Y; Dong S; Wang D
Bioorg Chem; 2017 Aug; 73():63-75. PubMed ID: 28618343
[TBL] [Abstract][Full Text] [Related]
30. C-terminal truncation exacerbates the aggregation and cytotoxicity of α-Synuclein: A vicious cycle in Parkinson's disease.
Ma L; Yang C; Zhang X; Li Y; Wang S; Zheng L; Huang K
Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3714-3725. PubMed ID: 30290273
[TBL] [Abstract][Full Text] [Related]
31. Echinacoside protects against MPTP/MPP
Chen C; Xia B; Tang L; Wu W; Tang J; Liang Y; Yang H; Zhang Z; Lu Y; Chen G; Yang Y; Zhao Y
Metab Brain Dis; 2019 Feb; 34(1):203-212. PubMed ID: 30426321
[TBL] [Abstract][Full Text] [Related]
32. Targeting α-Synuclein in Parkinson's Disease: Progress Towards the Development of Disease-Modifying Therapeutics.
Savitt D; Jankovic J
Drugs; 2019 Jun; 79(8):797-810. PubMed ID: 30982161
[TBL] [Abstract][Full Text] [Related]
33. α-Synuclein aggregation modulation: an emerging approach for the treatment of Parkinson's disease.
Singh SK; Dutta A; Modi G
Future Med Chem; 2017 Jun; 9(10):1039-1053. PubMed ID: 28632413
[TBL] [Abstract][Full Text] [Related]
34. A novel iron (II) preferring dopamine agonist chelator D-607 significantly suppresses α-syn- and MPTP-induced toxicities in vivo.
Das B; Rajagopalan S; Joshi GS; Xu L; Luo D; Andersen JK; Todi SV; Dutta AK
Neuropharmacology; 2017 Sep; 123():88-99. PubMed ID: 28533164
[TBL] [Abstract][Full Text] [Related]
35. Effect of curcumin analogs onα-synuclein aggregation and cytotoxicity.
Jha NN; Ghosh D; Das S; Anoop A; Jacob RS; Singh PK; Ayyagari N; Namboothiri IN; Maji SK
Sci Rep; 2016 Jun; 6():28511. PubMed ID: 27338805
[TBL] [Abstract][Full Text] [Related]
36. Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease.
He Q; Koprich JB; Wang Y; Yu WB; Xiao BG; Brotchie JM; Wang J
Mol Neurobiol; 2016 May; 53(4):2258-68. PubMed ID: 25972237
[TBL] [Abstract][Full Text] [Related]
37. A Cleaning Crew: The Pursuit of Autophagy in Parkinson's Disease.
Parekh P; Sharma N; Gadepalli A; Shahane A; Sharma M; Khairnar A
ACS Chem Neurosci; 2019 Sep; 10(9):3914-3926. PubMed ID: 31385687
[TBL] [Abstract][Full Text] [Related]
38. Scutellarin inhibits the uninduced and metal-induced aggregation of α-Synuclein and disaggregates preformed fibrils: implications for Parkinson's disease.
Zaidi FK; Deep S
Biochem J; 2020 Feb; 477(3):645-670. PubMed ID: 31939603
[TBL] [Abstract][Full Text] [Related]
39. Latrepirdine stimulates autophagy and reduces accumulation of α-synuclein in cells and in mouse brain.
Steele JW; Ju S; Lachenmayer ML; Liken J; Stock A; Kim SH; Delgado LM; Alfaro IE; Bernales S; Verdile G; Bharadwaj P; Gupta V; Barr R; Friss A; Dolios G; Wang R; Ringe D; Protter AA; Martins RN; Ehrlich ME; Yue Z; Petsko GA; Gandy S
Mol Psychiatry; 2013 Aug; 18(8):882-8. PubMed ID: 22869031
[TBL] [Abstract][Full Text] [Related]
40. Self-Assembled Cyclic d,l-α-Peptides as Generic Conformational Inhibitors of the α-Synuclein Aggregation and Toxicity: In Vitro and Mechanistic Studies.
Chemerovski-Glikman M; Rozentur-Shkop E; Richman M; Grupi A; Getler A; Cohen HY; Shaked H; Wallin C; Wärmländer SK; Haas E; Gräslund A; Chill JH; Rahimipour S
Chemistry; 2016 Sep; 22(40):14236-46. PubMed ID: 27539220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
